Showing 1 - 10 of 2,895
Persistent link: https://www.econbiz.de/10011946167
The COVID-19 crisis intensified decade-long debates on the interaction between intellectual property rights (IPRs), competition law and access to affordable life-saving treatments and vaccines. Compulsory licensing of patented medicines is a tried-and-tested method to expand access, particularly...
Persistent link: https://www.econbiz.de/10014541546
Disputes over the regulation of access to medicines are occurring in multiple transnational, national, and local venues. Competing groups of states and non-state actors shift horizontally and vertically among these forums in an effort to develop competing legal rules over the propriety of...
Persistent link: https://www.econbiz.de/10014129207
The United States represents the world’s largest market for pharmaceutical drugs. It is also the only advanced economy in the world that does not regulate drug prices. There is no upper threshold for the prices of medicines in the United States. List prices are instead set by manufacturers in...
Persistent link: https://www.econbiz.de/10013295329
This paper aims to analyze the interfaces between Brazilian Competition Law and the issue of access to medicines, with a special focus on abuse of industrial property rights and related exclusionary and exploitative effects. The paper analyzes the case law of Brazilian Administrative Council for...
Persistent link: https://www.econbiz.de/10013365665
The aim of this book is to identify the major drivers of change within the European healthcare systems and to evaluate risks and opportunities confronting pharmaceutical full-line wholesalers. These businesses are the most important link between pharmaceutical manufacturing and the point of sale;...
Persistent link: https://www.econbiz.de/10012689275
Persistent link: https://www.econbiz.de/10008665811
Persistent link: https://www.econbiz.de/10002518781
Persistent link: https://www.econbiz.de/10012497227